Review top news and interview highlights from the week ending September 2, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.
The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.
The risk-benefit assessment determined that there are no significant safety concerns.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.